Featured Articles

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of…
Read More...

Merck, known as MSD outside the United States and Canada, and VelosBio Inc. announced that the companies have entered into a definitive agreement pursuant to which Merck, through a…
Read More...

Bayer AG announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing…
Read More...

Prothena Corporation plc a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare…
Read More...

Pfizer Inc. and BioNTech SE announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine…
Read More...

Bristol Myers Squibb and MyoKardia, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash.…
Read More...

Pfizer Inc. announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from the…
Read More...

GlaxoSmithKline plc (GSK) announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and…
Read More...

Gilead Sciences, Inc. and Eisai Co., Ltd. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of…
Read More...

Moderna, Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid…
Read More...

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is…
Read More...

Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in…
Read More...

Pfizer Inc. and BioNTech SE announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19…
Read More...

Bayer and US-based Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery, have entered into a strategic collaboration agreement. The partnership will…
Read More...

Mylan N.V. announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for EUR…
Read More...

Grifols announced it has entered into a transaction to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. No additional…
Read More...

GeneCentric Therapeutics announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600…
Read More...

Pfizer Inc. and BioNTech SE announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate…
Read More...

Teva Pharmaceutical Industries Ltd. who holds (through its Japanese affiliates) with Takeda a joint business venture in the Japanese market, announced a new strategy for its local…
Read More...